Piracetam

ApprovedSmall molecule

UCB

Piracetam is one of 114 small molecule programs targeting Peripheral Vertigo. It is currently in Approved.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral VertigoActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Peripheral NeuropathyActive, not recruiting

AphasiaActive, not recruiting

Tardive DyskinesiaActive, not recruiting

Peripheral VertigoApproved

Active, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Peripheral NeuropathyApproved

Active, not recruiting

AphasiaApproved

Active, not recruiting

Tardive DyskinesiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Piracetam

UCB

Approved

1 4

Provigil

NNuvo Research GmbH

Phase 3

1 5

Xarelto

WWim Janssens

Phase 3

1 6

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 7

Viagra

VViatris Specialty LLC

Phase 3

1 8

Donepezil Hydrochloride

Eisai

Phase 3

3 9

Statins

Sanofi

Phase 3

1 10

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment2 trials

Piracetam for Treatment of Cocaine Addiction - 3

Completed·UUniversity of Pennsylvania·Phase 1·NCT00000198

Piracetam for Treatment of Cocaine Addiction, Phase II - 4

Withdrawn·UUniversity of Pennsylvania·Phase 1·NCT00000199

Peripheral Neuropathy1 trial

The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients

Not yet recruiting·—·Phase 4·NCT06479629·60 enrolled

Cognitive impairment1 trial

Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

Completed· UCB logo

UCB·N/A·NCT00567060·676 enrolled

Aphasia1 trial

A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke

Terminated· UCB logo

UCB·Phase 4·NCT01883011·571 enrolled

Tardive Dyskinesia1 trial

Piracetam for Treatment Tardive Dyskinesia

Completed·—·Phase 3·NCT00190008·40 enrolled

2 more indications

Peripheral Vertigo1 trial

Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo

Completed·KKocaeli University·Phase 4·NCT01890538·94 enrolled

Unspecified2 trials

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Subtherapeutic Dose of Piracetam as a Therapy Adherence Marker

Unknown status·TThe Netherlands Cancer Institute·Phase 4·NCT05918341·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Piracetam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Piracetam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Piracetam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UCB

Piracetam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment2 trials

Peripheral Neuropathy1 trial

Cognitive impairment1 trial

Aphasia1 trial

Tardive Dyskinesia1 trial

Peripheral Vertigo1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News